Table 3

Meth-evoked motor activity: SDZ Ser 082 and SB 206553 effects
Horizontal Activity Total Distance Vertical Activity Stereotypy Count
Vehicle 8797 ± 738 3832 ± 336 1142 ± 122 477 ± 33
1.0 mg/kg SDZ 8598 ± 858 3723 ± 392 996 ± 190 460 ± 29
Vehicle 7448 ± 1025 3113 ± 444 797 ± 141 446 ± 29
5.0 mg/kg SB206 9067 ± 711 4326 ± 572 594 ± 120 471 ± 18
Vehicle 8429 ± 1133 3705 ± 692 1124 ± 201 471 ± 26
10.0 mg/kg SB206 6448 ± 1276 2245 ± 499 398 ± 91** 394 ± 58

Rats that had undergone repeated cue reactivity testing were withdrawn from methamphetamine and assessed for methamphetamine-evoked (1.0 mg/kg) motor effects after a 30 min pretreatment with 1.0 mg/kg SDZ Ser 082 (SDZ; 5-HT2C receptor antagonist), 5.0 mg/kg SB 206553 (SB206; putative 5-HT2C receptor inverse agonist), 10.0 mg/kg SB206 and respective vehicles. Serotonin2C receptor antagonism had no effect on methamphetamine-evoked motor activity whereas inverse agonism with 10.0 mg/kg SB206 significantly attenuated vertical activity (paired t-test; **p < 0.01).

Graves and Napier

Graves and Napier BMC Neuroscience 2012 13:65   doi:10.1186/1471-2202-13-65

Open Data